• BankM reiterated its Buy rating on Bio-Gate on Nov. 10, 2026, with a 12-month price target of EUR 5.01–6.44.
• First-half 2026 revenue fell 17.7% to EUR 2.83 million, driven primarily by weakness in dermatological cosmetics and wound care.
• Capital increases raised EUR 1.16 million gross, which BankM expects to provide sufficient liquidity for 2026–27.
• The analyst estimates free cash outflow of about EUR 1 million in 2026, including interest, with internal financing capacity possible from 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Gate AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27406) on November 10, 2026, and is solely responsible for the information contained therein.